ALLOGENE THERAPEUTICS, INC.

(ALLO)
  Report
Real-time Estimate Cboe BZX  -  12:12 2022-06-28 pm EDT
11.44 USD   -2.26%
06/24ALLOGENE THERAPEUTICS, INC.(NASDAQGS : ALLO) dropped from Russell 2500 Growth Index
CI
06/24ALLOGENE THERAPEUTICS, INC.(NASDAQGS : ALLO) dropped from Russell 3000E Growth Index
CI
06/24ALLOGENE THERAPEUTICS, INC.(NASDAQGS : ALLO) dropped from Russell 3000 Growth Index
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

B. Riley Lowers Allogene Therapeutics' PT to $21 from $30 on Heels of Regulatory Requirement for ALLO-647 Lymphodepleting Antibody, Keeps Buy Rating

02/28/2022 | 09:42am EDT


© MT Newswires 2022
All news about ALLOGENE THERAPEUTICS, INC.
06/24ALLOGENE THERAPEUTICS, INC.(NASDAQGS : ALLO) dropped from Russell 2500 Growth Index
CI
06/24ALLOGENE THERAPEUTICS, INC.(NASDAQGS : ALLO) dropped from Russell 3000E Growth Index
CI
06/24ALLOGENE THERAPEUTICS, INC.(NASDAQGS : ALLO) dropped from Russell 3000 Growth Index
CI
06/24ALLOGENE THERAPEUTICS, INC.(NASDAQGS : ALLO) dropped from Russell Small Cap Comp Growth In..
CI
06/24ALLOGENE THERAPEUTICS, INC.(NASDAQGS : ALLO) dropped from Russell 2000 Growth Index
CI
06/23INSIDER SELL : Allogene Therapeutics
MT
06/17ALLOGENE THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders, Financi..
AQ
06/13TRANSCRIPT : Allogene Therapeutics, Inc. Presents at Goldman Sachs 43rd Annual Global Heal..
CI
06/08Allogene Therapeutics Shares Rise 9% After FDA Approves Trial for Lymphoma
DJ
06/08Allogene's Potential Cancer Treatment Gets FDA's Regenerative Medicine Advanced Therapy..
MT
More news
Analyst Recommendations on ALLOGENE THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 0,12 M - -
Net income 2022 -367 M - -
Net cash 2022 326 M - -
P/E ratio 2022 -4,54x
Yield 2022 -
Capitalization 1 680 M 1 680 M -
EV / Sales 2022 11 138x
EV / Sales 2023 253x
Nbr of Employees 334
Free-Float 55,8%
Chart ALLOGENE THERAPEUTICS, INC.
Duration : Period :
Allogene Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALLOGENE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 19
Last Close Price 11,70 $
Average target price 25,71 $
Spread / Average Target 120%
EPS Revisions
Managers and Directors
David D. Chang President, Chief Executive Officer & Director
Eric Schmidt Chief Financial Officer
Arie S. Belldegrun Executive Chairman
Alison Moore Chief Technical Officer
Barbra Sasu Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
ALLOGENE THERAPEUTICS, INC.-17.69%1 763
GILEAD SCIENCES, INC.-13.12%79 122
VERTEX PHARMACEUTICALS33.22%74 821
REGENERON PHARMACEUTICALS, INC.-3.01%65 993
WUXI APPTEC CO., LTD.-12.75%44 742
BIONTECH SE-48.01%32 574